Advertisement

Tumor Biology

, Volume 35, Issue 3, pp 2655–2659 | Cite as

Comparative effectiveness of radiofrequency ablation with or without transarterial chemoembolization for hepatocellular carcinoma

  • Qing-Feng Kong
  • Jun-Bo Jiao
  • Qian-Qian Chen
  • Long Li
  • Dong-Guang Wang
  • Bin Lv
Research Article

Abstract

The aim of this study is to compare the overall survival in patients with hepatocellular carcinoma (HCC) treated with radiofrequency ablation (RFA) and transarterial chemoembolization (TACE) versus RFA alone. All eligible studies were collected from the PubMed, the Cochrane Library, and the Embase electronic databases. The outcomes were overall survival rates. We used odds ratios to assess the strength of the association, and 95 % confidence intervals give a sense of the precision of the estimate. Statistical analyses were performed by Review Manager 5.0 and Stata 11.0. A total of 19 available studies were considered in the present meta-analysis. When all groups were pooled, meta-analysis showed that RFA plus TACE significantly improved the survival rates of patients with HCC at 1, 3, and 5 years compared with RFA alone. The combination of RFA with TACE has advantages in improving overall survival rate, and provides better prognosis for HCC patients.

Keywords

Hepatocellular carcinoma Radiofrequency ablation Transarterial chemoembolization 

Notes

Conflicts of interest

None

References

  1. 1.
    Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011;61:69–90.PubMedCrossRefGoogle Scholar
  2. 2.
    Guo D, Hou X, Zhang H, Sun W, Zhu L, Liang J, et al. More expressions of BDNF and TrkB in multiple hepatocellular carcinoma and anti-BDNF or K252a induced apoptosis, supressed invasion of HepG2 and HCCLM3 cells. J Exp Clin Cancer Res. 2011;30:9.CrossRefGoogle Scholar
  3. 3.
    Abdel aziz MT, El Asmar MF, Atta HM, Mahfouz S, Fouad HH, Roshdy NK, et al. Efficacy of mesenchymal stem cells in suppression of hepatocarcinorigenesis in rats: possible role of Wnt signaling. J Exp Clin Cancer Res. 2011;30:49.PubMedCentralPubMedCrossRefGoogle Scholar
  4. 4.
    Li FQ, Zhang SX, An LX, Gu YQ. In vivo molecular targeting effects of anti-Sp17- ICG-Der-02 on hepatocellular carcinoma evaluated by an optical imaging system. J Exp Clin Cancer Res. 2011;30:25.PubMedCentralPubMedCrossRefGoogle Scholar
  5. 5.
    Tveteraas IH, Müller KM, Aasrum M, Ødegård J, Dajani O, Guren T, et al. Mechanisms involved in PGE2-induced transactivation of the epidermal growth factor receptor in MH1C1 hepatocarcinoma cells. J Exp Clin Cancer Res. 2012;31:72.PubMedCentralPubMedCrossRefGoogle Scholar
  6. 6.
    Tung-Ping Poon R, Fan ST, Wong J. Risk factors, prevention, and management of postoperative recurrence after resection of hepatocellular carcinoma. Ann Surg. 2000;232:10–24.PubMedCentralPubMedCrossRefGoogle Scholar
  7. 7.
    Lin SM, Lin CJ, Lin CC, Hsu CW, Chen YC. Radiofrequency ablation improves prognosis compared with ethanol injection for hepatocellular carcinoma < or =4 cm. Gastroenterology. 2004;127:1714–23.PubMedCrossRefGoogle Scholar
  8. 8.
    Shiina S, Teratani T, Obi S, Sato S, Tateishi R, Fujishima T, et al. A randomized controlled trial of radiofrequency ablation with ethanol injection for small hepatocellular carcinoma. Gastroenterology. 2005;129:122–30.PubMedCrossRefGoogle Scholar
  9. 9.
    Lu DS, Yu NC, Raman SS, Limanond P, Lassman C, Murray K, et al. Radiofrequency ablation of hepatocellular carcinoma: treatment success as defined by histologic examination of the explanted liver. Radiology. 2005;234:954–60.PubMedCrossRefGoogle Scholar
  10. 10.
    Yang W, Chen MH, Wang MQ, Cui M, Gao W, Wu W, et al. Combination therapy of radiofrequency ablation and transarterial chemoembolization in recurrent hepatocellular carcinoma after hepatectomy compared with single treatment. Hepatol Res. 2009;39:231–40.PubMedCrossRefGoogle Scholar
  11. 11.
    Peng ZW, Chen MS, Liang HH, Gao HJ, Zhang YJ, Li JQ, et al. A case–control study comparing percutaneous radiofrequency ablation alone or combined with transcatheter arterial chemoembolization for hepatocellular carcinoma. Eur J Surg Oncol. 2010;36:257–63.PubMedCrossRefGoogle Scholar
  12. 12.
    Hu YQ. Radiofrequency ablation and transcatheter arterial chemoembolization in primary hepatic carcinoma. Contemp Med. 2011;17:232–3.Google Scholar
  13. 13.
    Kim JW, Kim JH, Won HJ, Shin YM, Yoon HK, Sung KB, et al. Hepatocellular carcinomas 2–3 cm in diameter: transarterial chemoembolization plus radiofrequency ablation versus radiofrequency ablation alone. Eur J Radiol. 2012;81:e189–93.PubMedCrossRefGoogle Scholar
  14. 14.
    Kim JH, Won HJ, Shin YM, Kim SH, Yoon HK, Sung KB, et al. Medium-sized (3.1–5.0 cm) hepatocellular carcinoma: transarterial chemoembolization plus radiofrequency ablation versus radiofrequency ablation alone. Ann Surg Oncol. 2011;18:1624–9.PubMedCrossRefGoogle Scholar
  15. 15.
    Shen SQ, Xiang JJ, Xiong CL, Wu SM, Zhu SS. Intraoperative radiofrequency thermal ablation combined with portal vein infusion chemotherapy and transarterial chemoembolization for unresectable HCC. Hepatogastroenterology. 2005;52:1403–7.PubMedGoogle Scholar
  16. 16.
    Kang CB, Xu HB, Wang SL, Rui B. Treatment of large hepatoma by TACE in combination with RFA. Chin J Hepatobiliary Surg. 2007;13:828–30.Google Scholar
  17. 17.
    Wang YB, Chen MH, Yan K, Yang W, Dai Y, Yin SS. Quality of life of primary hepatocellular carcinoma patients after radiofrequency ablation. Ai Zheng. 2005;24:827–33.PubMedGoogle Scholar
  18. 18.
    Yang P, Liang M, Zhang Y, Shen B. Clinical application of a combination therapy of lentinan, multi-electrode RFA, and TACE in HCC. Adv Ther. 2008;25:787–94.PubMedCrossRefGoogle Scholar
  19. 19.
    Xu L, Li P, Chen MS, Pang XH, Gao HJ, Peng ZW, et al. Percutaneous radiofrequency ablation combined with other minimally invasive treatments for recurrent hepatocellular carcinoma after hepatectomy. Zhonghua Wai Ke Za Zhi. 2008;46:1617–20.PubMedGoogle Scholar
  20. 20.
    Luo ZG, Xiong K, Duan QW, Ren JM, Wang DW, Li C. Therapy of 3-dimension conform technology-guided radiofrequency ablation and transcatheter arterial chemoembolization in primary hepatic carcinoma. Yunyang Yi Xue Yuan Xue Bao. 2008;27:22–5.Google Scholar
  21. 21.
    Li ZR, Kang Z, Qian JS, Zhu KS, Jiang ZB, Huang MS, et al. Radiofrequency ablation with or without transcatheter arterial chemoembolization for management of hepatocellular carcinoma. Nan Fang Yi Ke Da Xue Xue Bao. 2007;27:1749–51.PubMedGoogle Scholar
  22. 22.
    Shibata T, Isoda H, Hirokawa Y, Arizono S, Shimada K, Togashi K. Small hepatocellular carcinoma: is radiofrequency ablation combined with transcatheter arterial chemoembolization more effective than radiofrequency ablation alone for treatment? Radiology. 2009;252:905–13.PubMedCrossRefGoogle Scholar
  23. 23.
    Cheng BQ, Jia CQ, Liu CT, Fan W, Wang QL, Zhang ZL, et al. Chemoembolization combined with radiofrequency ablation for patients with hepatocellular carcinoma larger than 3 cm: a randomized controlled trial. JAMA. 2008;299:1669–77.PubMedCrossRefGoogle Scholar
  24. 24.
    Aikata H, Shirakawa H, Takaki S. Radiofrequency ablation combined with transcatheter arterial chemoembolization for small hepatocellular carcinoma. Hepatology. 2006;44:A487.CrossRefGoogle Scholar
  25. 25.
    Morimoto M, Numata K, Kondou M, Nozaki A, Morita S, Tanaka K. Midterm outcomes in patients with intermediate-sized hepatocellular carcinoma: a randomized controlled trial for deter-mining the efficacy of radiofrequency ablation combined with transcatheter arterial chemoembolization. Cancer. 2010;116:5452–60.PubMedCrossRefGoogle Scholar
  26. 26.
    Shen L, Chen MH, Yan K, Yang W, Gao W, Liao SR, et al. Clinical application of a combination therapy of percutaneous radiofrequency and transcatheter arterial chemoembolization in large hepatic tumors. Zhonghua Chao Sheng Yin Xiang Xue Za Zhi. 2004;13:577–80.Google Scholar
  27. 27.
    Zhang HC, Liang J. Radiofrequency ablation or transcatheter arterial chemoembolization for management of hepatocellular carcinoma. Zhong Guo Yi Shi Jin Xiu Za Zhi. 2007;30:67–8.Google Scholar
  28. 28.
    Liang MH. Transcatheter arterial chemoembolization combined with radiofrequency ablation for the management of hepatocellular carcinoma. Zhong Guo Lao Nian Yi Xue Za Zhi. 2011;31:2862–4.Google Scholar
  29. 29.
    Zhang H, Qi C, Li L, Luo F, Xu Y. Clinical significance of NUCB2 mRNA expression in prostate cancer. J Exp Clin Cancer Res. 2013;32:56.PubMedCentralPubMedCrossRefGoogle Scholar
  30. 30.
    Zhang H, Qi C, Wang A, Yao B, Li L, Wang Y, et al. Prognostication of prostate cancer based on NUCB2 protein assessment. NUCB2 in prostate cancer. 2013;32:77.Google Scholar
  31. 31.
    Zhang H, Ma H, Xu Y, Li L. Association of SMAD7 rs12953717 polymorphism with cancer: a meta-analysis. PLoS ONE. 2013;8:e58170.PubMedCentralPubMedCrossRefGoogle Scholar
  32. 32.
    Zhang H, Ma H, Li L, Zhang Z, Xu Y. Association of methylenetetrahydrofolate dehydrogenase 1 polymorphisms with cancer: a meta-analysis. PLoS One. 2013;8:e69366.PubMedCentralPubMedCrossRefGoogle Scholar
  33. 33.
    Zhang H, Xu Y, Zhang Z, Liu R, Ma B. Association between COX-2 rs2745557 polymorphism and prostate cancer risk: a systematic review and meta-analysis. BMC Immunol. 2012;13:14.PubMedCentralPubMedCrossRefGoogle Scholar
  34. 34.
    Zhang H, Li L, Xu Y. CYP1B1 polymorphisms and susceptibility to prostate cancer: a meta-analysis. PLoS One. 2013;8:e68634.PubMedCentralPubMedCrossRefGoogle Scholar
  35. 35.
    Li GC, Ye QH, Dong QZ, Ren N, Jia HL, Qin LX. TGF beta1 and related-Smads contribute to pulmonary metastasis of hepatocellular carcinoma in mice model. J Exp Clin Cancer Res. 2012;31:93.PubMedCentralPubMedCrossRefGoogle Scholar
  36. 36.
    You N, Liu W, Tang L, Zhong X, Ji R, Zhang N, et al. Tg737 signaling is required for hypoxia-enhanced invasion and migration of hepatoma cells. J Exp Clin Cancer Res. 2012;31:75.PubMedCentralPubMedCrossRefGoogle Scholar
  37. 37.
    Shojaei F, Scott N, Kang X, Lappin PB, Fitzgerald AA, Karlicek S, et al. Osteopontin induces growth of metastatic tumors in a preclinical model of non-small lung cancer. J Exp Clin Cancer Res. 2012;31:26.PubMedCentralPubMedCrossRefGoogle Scholar
  38. 38.
    Yu XC, Xu M, Xu SF, Song RX. Long-term outcomes of epiphyseal preservation and reconstruction with inactivated bone for distal femoral osteosarcoma of children. Orthop Surg. 2012;4(1):21–7.PubMedCrossRefGoogle Scholar
  39. 39.
    Hu YC, Ji JT, Lun DX. Intraoperative microwave inactivation in situ of malignant tumors in the scapulas. Orthop Surg. 2011;3(4):229–35.PubMedCrossRefGoogle Scholar

Copyright information

© International Society of Oncology and BioMarkers (ISOBM) 2013

Authors and Affiliations

  • Qing-Feng Kong
    • 1
  • Jun-Bo Jiao
    • 1
  • Qian-Qian Chen
    • 1
  • Long Li
    • 1
  • Dong-Guang Wang
    • 1
  • Bin Lv
    • 1
  1. 1.Department of UltrasoundJining NO.1 People’s HospitalJiningChina

Personalised recommendations